source
- FDA flags safety concern after four deaths in schizophrenia drug trialThe U.S. Food and Drug Administration issued a warning after four participants died while receiving an experimental treatment for schizophrenia in a clinical study. The agency described the observ…
- Aspen Neuroscience and Bambusa Therapeutics announce plans to go public amid biotech IPO surgeAspen Neuroscience, a cell therapy company backed by Gilead, and Bambusa Therapeutics, an I&I biotech founded by former BioNTech scientists, have each filed paperwork to launch initial public offer…